Emmaus Life Sciences annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Emmaus Life Sciences's operating margin was 1.85% for fiscal 2025.
View full Emmaus Life Sciences company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 1.85% | +13.23 pp |
| 2024 | 2024-12-31 | −11.37% | −23.33 pp |
| 2023 | 2023-12-31 | 11.96% | +47.77 pp |
| 2022 | 2022-12-31 | −35.81% | −6.08 pp |
| 2021 | 2021-12-31 | −29.73% | −29.60 pp |
| 2020 | 2020-12-31 | −0.14% | +19.69 pp |
| 2019 | 2019-12-31 | −19.83% | +758.95 pp |
| 2018 | 2018-09-30 | −778.78% | +4749.31 pp |
| 2017 | 2017-09-30 | −5,528.09% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 60.00% | +73.14 pp |
| Q1 2026 | 2026-03-31 | −41.52% | −0.79 pp |
| Q4 2025 | 2025-12-31 | 23.00% | +39.92 pp |
| Q3 2025 | 2025-09-30 | 20.57% | +5.59 pp |
| Q2 2025 | 2025-06-30 | −13.13% | −23.96 pp |
| Q1 2025 | 2025-03-31 | −40.73% | +68.61 pp |
| Q4 2024 | 2024-12-31 | −16.92% | −36.09 pp |
| Q3 2024 | 2024-09-30 | 14.99% | +14.51 pp |
| Q2 2024 | 2024-06-30 | 10.82% | −20.09 pp |
| Q1 2024 | 2024-03-31 | −109.34% | −92.09 pp |
| Q4 2023 | 2023-12-31 | 19.17% | +43.09 pp |
| Q3 2023 | 2023-09-30 | 0.48% | +13.84 pp |
| Q2 2023 | 2023-06-30 | 30.91% | +64.50 pp |
| Q1 2023 | 2023-03-31 | −17.25% | +77.62 pp |
| Q4 2022 | 2022-12-31 | −23.91% | +140.49 pp |
| Q3 2022 | 2022-09-30 | −13.36% | −12.83 pp |
| Q2 2022 | 2022-06-30 | −33.59% | −41.03 pp |
| Q1 2022 | 2022-03-31 | −94.87% | −64.60 pp |
| Q4 2021 | 2021-12-31 | −164.40% | −170.18 pp |
| Q3 2021 | 2021-09-30 | −0.54% | −0.68 pp |
| Q2 2021 | 2021-06-30 | 7.44% | +42.65 pp |
| Q1 2021 | 2021-03-31 | −30.27% | −46.58 pp |
| Q4 2020 | 2020-12-31 | 5.77% | −4.53 pp |
| Q3 2020 | 2020-09-30 | 0.14% | +70.40 pp |
| Q2 2020 | 2020-06-30 | −35.21% | −37.32 pp |
| Q1 2020 | 2020-03-31 | 16.31% | +43.52 pp |
| Q4 2019 | 2019-12-31 | 10.31% | +703.02 pp |
| Q3 2019 · Sep 30 | 2019-09-30 | −70.26% | −26.61 pp |
| Q3 2019 · Jun 30 | 2019-06-30 | 2.11% | +745.90 pp |
| Q2 2019 | 2019-03-31 | −27.21% | +545.28 pp |
| Q1 2019 | 2018-12-31 | −692.72% | +1565.97 pp |
| Q4 2018 | 2018-09-30 | −43.65% | +3803.38 pp |
| Q3 2018 | 2018-06-30 | −743.78% | — |
| Q2 2018 | 2018-03-31 | −572.49% | — |
| Q1 2018 | 2017-12-31 | −2,258.69% | — |
| Q3 2017 | 2017-06-30 | −3,847.03% | — |
Over the last five reported fiscal years, Emmaus Life Sciences's operating margin increased from −0.14% to 1.85%, a change of +1.99 percentage points. The latest reported quarter, Q2 2026, shows 60.00%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Emmaus Life Sciences filings at SEC.gov ↗